PT  - JOURNAL ARTICLE
AU  - Hu, Xintao
AU  - Karthigeyan, Krithika P.
AU  - Herbek, Savannah
AU  - Valencia, Sarah M.
AU  - Jenks, Jennifer A.
AU  - Webster, Helen
AU  - Miller, Itzayana G.
AU  - Connors, Megan
AU  - Pollara, Justin
AU  - Andy, Caroline
AU  - Gerber, Linda M.
AU  - Walter, Emmanuel B.
AU  - Edwards, Kathryn M.
AU  - Bernstein, David I.
AU  - Hou, Jacob
AU  - Koch, Matthew
AU  - Panther, Lori
AU  - Carfi, Andrea
AU  - Wu, Kai
AU  - Permar, Sallie R.
TI  - Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses than that of the Partially Effective gB/MF59 Vaccine
AID  - 10.1101/2023.08.02.23293386
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.02.23293386
4099  - http://medrxiv.org/content/early/2023/08/06/2023.08.02.23293386.short
4100  - http://medrxiv.org/content/early/2023/08/06/2023.08.02.23293386.full
AB  - Background The MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated ~50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting efforts to improve this vaccine design might yield a vaccine suitable for licensure. A vaccine candidate employing nucleoside-modified mRNAs encoding HCMV gB and pentameric complex (PC) encapsulated in lipid nanoparticle, mRNA-1647, is currently in late-stage efficacy trials. Yet, its immunogenicity has not been compared to the partially-effective gB/MF59 vaccine.Methods We assessed neutralizing and Fc-mediated IgG effector antibody responses induced by mRNA-1647, a vaccine comprising an equal mass of 6 mRNAs encoding gB and PC antigens, in both HCMV seropositive and seronegative vaccinees from a first-in-human clinical trial through 1-year following 3rd vaccination using a systems serology approach. Further, we compared peak anti-gB antibody responses in seronegative mRNA-1647 vaccinees to that of seronegative female adolescent gB/MF59 vaccine recipients.Results mRNA-1647 vaccination boosted pre-existing HCMV-specific IgG responses in seropositive vaccinees, including neutralizing and Fc-mediated effector antibody responses. In seronegative vaccinees, mRNA-1647 induced durable and functional HCMV-specific IgG responses. Elicited gB-specific IgG responses were lower than the PC-specific IgG responses. Additionally, gB-specific IgG and antibody-dependent cellular phagocytosis (ADCP) responses were lower than those elicited by gB/MF59. However, mRNA-1647 elicited robust neutralization and high antibody-dependent cellular cytotoxicity (ADCC) responses.Conclusions mRNA-1647 vaccination induced polyfunctional and durable HCMV-specific antibody responses. mRNA-1647-elicited gB-specific IgG responses were lower than PC-specific IgG responses and lower than those elicited by the partially effective gB/MF59. However, higher neutralization and ADCC responses were elicited by mRNA-1647 than gB/MF59.Clinical Trials Registration ClinicalTrials.gov (NCT03382405, mRNA-1647) and (NCT00133497, gB/MF59).Summary mRNA-1647 HCMV vaccine elicited polyfunctional and durable antibody responses in humans. While the mRNA-1647-elicited glycoprotein B (gB)-specific IgG responses were lower than that of the moderately-effective gB/MF59 vaccine, the pentameric complex (PC)-specific IgG responses were strong.Competing Interest StatementS.R.P. is a consultant to Moderna, Merck, Pfizer, GSK, Dynavax, and Hoopika CMV vaccine programs and leads sponsored programs with Moderna and Merck. S.R.P. also serves on the board of the National CMV Foundation and as an educator on CMV for Medscape. E.B.W has received funding support from Pfizer, Moderna, Sequiris, Najit Technologies Inc, and Clinetic for the conduct of clinical trials and clinical research. E.B.W has served as an advisor to Vaxcyte and consultant to ILiAD biotechnologies. J.H., M.K., K.W., A.C. has Moderna company stocks. The other authors have no financial conflicts of interest.Clinical TrialNCT03382405 and NCT00133497Funding StatementThis work was supported by Moderna Therapeutics SRA Project# OA22BEA4 and NIH R21 project # 5R21 AI136556 to S.R.P.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board (IRB) approval was obtained for the gB/MF59 cohort from the Cincinnati Childrens Hospital Medical Center, and samples were provided by the NIAID Vaccine Treatment and Evaluation Unit (grant #5R21 AI136556). For the mRNA-1647 study conducted by Moderna, the study protocol, amendments, and informed consent form were reviewed and approved by the Advarra IRB. Written informed consent was obtained from all participants prior to study recruitment and procedures. The study protocol adhered to all applicable national, state, and local laws or regulations, the principles of the International Council for Harmonisation harmonized tripartite guideline E6(R2): Good Clinical Practice and of the Declaration of Helsinki. All mRNA-1647 samples transferred to Duke and WCM from Moderna were de-identified, and the analysis of de-identified samples was exempt from human subjects research designation by the IRBs of Duke and WCM.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript